Handbook of Vitamin D – 700 pages – 2013
Handbook of vitamin D in human health: vitamin D in human health, Prevention, treatment and toxicity
Edited by: Ronald Ross Watson
Human Health Handbooks no. 4 ISSN 2212-375X
Wageningen Academic Publishers
See also Vitamin D Life
Vitamin D – 3rd Edition book 2011
[dl2668] if Registered
Buy a print copy of this book at www.WageningenAcademic.com/HHH04
ISBN: 978-90-8686-210-8 e-ISBN: 978-90-8686-765-3 DOI: 10.3920/978-90-8686-765-3
First published, 2013
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned. Nothing from this publication may be translated, reproduced, stored in a computerised system or published in any form or in any manner, including electronic, mechanical, reprographic or photographic, without prior written permission from the publisher: Wageningen Academic Publishers P.O. Box 220 6700 AE Wageningen The Netherlands
www.WageningenAcademic.com [email protected]
The individual contributions in this publication and any liabilities arising from them remain the responsibility of the authors.
©Wageningen Academic Publishers The Netherlands, 2013
The publisher is not responsible for possible damages, which could be a result of content derived from this publication.
Overview of key vitamin D modified conditions
1. Vitamin D deficiency in the 21st century: an overview 13 S.S. Oberhelman and T.D. Thacher
2. Vitamin D in health of seniors 39 F. Lauretani, M. Maggio, C. Ruggiero, G.P. Ceda and L. Ferrucci
3. Vitamin D supplementation and public health policy 53 R. Babaria and R.R. Watson;
Vitamin D and musculoskeletal health
4. Vitamin D and fall risk 67 J. Basran, R.L. Duckham and D.B. Hogan
5. The beneficial effects of higher (adequate) vitamin D status on bone growth and muscle strength in children and adolescents 83 L.H. Foo and S.J. Whiting
6. Hypovitaminosis D and muscle strength 97 T. Songpatanasilp
7. Vitamin D and growth 115 H.T. Viljakainen and E. Hyppónen
8. Vitamin D and arthritis 137 U.J. Haque
9. High-dose vitamin D supplementation in the elderly 147 C.J. Bacon
Vitamin D and chronic disease
10. Vitamin D deficiency and premature death 175 A. Zittermann and S. Prokop
11. Vitamin D and hyperparathyroidism in patients with chronic kidney disease 193 D. Hansen
12. Diseases affected by vitamin D: sun exposure 207 W.B. Grant
13. Immune modulation by UV: role of vitamin D 227 P.H. Hart and S. Gorman
14. Vitamin D and periodontal disease N. Garcia, D. Miley and D.A. Dixon 243
15. Vitamin D and cystic fibrosis 255 T. Pincikova and M. Flodstróm-Tullberg
Vitamin D and infectious disease
16. Vitamin D and respiratory infections in infants and toddlers: a nutri-shine perspective 277 .V. Balan, U.S. Babu, D.E. Godar andM.S. Calvo
17. Vitamin D in HIV/AIDS: a role? 299 J.-P. Viard and J.-C. Souberbielle
18. Vitamin D and tuberculosis 321 K. vinh quócLUóngandL.T.H. Nguyen
19. Vitamin D and dental health 355 E. Jordan, S. Davis, P. Rakes, L.K. McCauley and J. Bashutski
20. Inflammation and vitamin D 373 X. Guillot, C. Prati, N. Saidenberg-Kermanach, L. Semerano, G. Falgarone, M.C. Boissier and D. Wendling
Vitamin D and cancer
21. Vitamin D in the prevention and treatment of pancreatic cancer 393 T.C. Chen and K.C. Chiang
22. Vitamin D and melanoma 419 J.A. Newton-Bishop and J.A. Randerson-Moor
23. Vitamin D autocrine system and prostate cancer prevention and treatment 445 T.C. Chen
24. Vitamin D and esophageal cancer 465 H.G. Coleman, M.M. Cantwell and L.J. Murray
25. Monitoring in vivo immune modulation by vitamin D in multiple sclerosis 475 A.-H. Muris, J. Damoiseaux and J. Smolders.
26. Vitamin D and insulin sensitivity 503 B. Larrick, S. Donkin and D. Teegarden
27. Vitamin D and diabetes mellitus: where are we? J. Liu 527
28. Vitamin D and cardiovascular risk: hype or new hope? 549 J.L. Anderson and J.B. uhlestein
29. Vitamin D and transplantation 567 M. Courbebaisse, J.C. Souberbielle and E. Thervet
30. Vitamin D and bone health among people with epilepsy 589 R.A. Shellhaas, R.K. Singh and S.M. Joshi;
Women and children
31. Neonatal effects of enhanced vitamin D and vitamin D for premature infants 609 H.K. Linke
32. Lactation and vitamin D 633 S.N. Taylor, C.L. Wagner and B.W. Hollis
33. Vitamin D replacement in pregnant women in developing countries 651 M.T. Sahu and M. Sahu
34. Vitamin D in pregnancy 671 D. Dror
35. Design and rationale of the VITamin D and OmegÁ-3 TriaL (VITAL) 693 S.S. Bassuk and .E. Manson
Index
About the edtior 729
Index
{SPLIT(fixedsize="y" colsize="330px|330px|330px")}
A
aBMD 85
ABPA 254, 262
absorption 19
accelerated aging 307
Acinar cells 394
acute lower respiratory infection - See: acute rejection - See: AR adaptive immunity
suppression 430
adenocarcinomas 464
adipocytes 504
adiponectin 513
gene 569
adipose tissue 513
adiposity 154, 512, 532, 610
adolescent
girls 86, 652
pregnancy 652 adverse
effects supplementation 122, 680
events 610
pregnancy 533
aetiology of melanoma 425
age
effects 70
-specific dietary intake 283
aggressive periodontitis 358
aging
accelerated 307
skin 148
telomeric 180
albuminuria 202
alcohol 392
alfacalcidol 74, 198
allelic variations in vitamin D receptor 326
allergic
asthma 228
bronchopulmonary aspergillosis - See:ABPA
response 375 allergy
food ~ 215
predisposition 677 ALRI 289, 638
altitude 215
alveolar
bone 355, 365
bone resorption 242
ALRI - crest heights 245
- ridge resorption 243
type II pneumocytes 285
American Academy of Pediatrics recommendations 619
AMP-activated protein kinase 513
analogs 198, 381
- efficacy 259
noncalcemic 401
ancillary studies 701
angiogenesis 186, 332, 399
ankylosing spondylitis patients 490
anorexia 658
antenatal services
- in developing countries 657
in rural areas 658
anthropometry 658
in newborn infants 650, 658
anti-angiogenic effects 428
anticancer immune response 423
anticarcinogenic effects 397, 468
anticonvulsant effect 597
antifracture efficacy 108
antigen 230
- presenting cell - See: APC
specific antibody 490
anti-inflammatory
effects 356
properties 246 antimicrobial
activity 247, 375
peptides 261, 286
antioxidants 426
antiproliferative
effect 397, 427
properties 185 antirachitic
activity 633, 642
deficient foods 16
metabolites 641 antiretroviral
drugs 299, 305
treatment 299 antiseizure
drugs 589
medications and bone metabolism 593
antitumor activity 401
APC 476, 492
apoptosis 186, 397, 420, 445, 468, 511
AR 573
areal bone mineral density - See: aBMD
arteriosclerosis in renal patients 570
asthma 232, 287, 677
allergic 228
atmospheric pollution 15, 651
atrial fibrillation 558
attachment apparatus of teeth 355
autoimmune
disease 139, 377, 475
encephalomyelitis 478
thyroiditis 380
autoimmunity 140
autophagy 309
B
Bacillus Calmette Guerin vaccination -
See: BCG vaccination bacterial vaginosis - See: BV
Barrett's esophagus 466, 468
baseline blood sample 699
B cells 377, 490
BCG vaccination 330
BD 488
Behcet's disease - See: BD
beta cells - See: pancreatic (3-cells
bile 502
biomarker 277
birth
status 636
weight 675
bisphosphonates 255
BMC 86
in neonates 675 BMD 108, 142, 157, 255
in epilepsy patients 591
in formula-fed infants 639
in HIV patients 307
BMI 302, 427
body mass index - See: BMI bone
as a critical endocrine organ 534
cross-sectional area 118
density scans 598
development 616
geometry 86
mineral content - See: BMC
mineral density - See: BMD; See also: aBMD (areal BMD); See also: vBMD (volumetric BMD)
mineralization 635
reabsorbing osteoclasts 379
resorption 358
bone health 526, 529, 695
breastfeeding infants 637
guidelines 277
indicator 679
infants 610
post-menopausal 633
reduced 425
supplementation 637 bone loss
after transplantation 566, 568
cortical 42 bone mass 88
accrual 116
mandibular 245
peak 84 bone size
and diabetic risk 533
and osteocalcin 534 bone turnover 85, 109
in epilepsy patients 592
markers 118, 157
brain 677
breast cancer 24, 184
breastfed infants 636, 637
supplementation 21, 638, 639
breastfeeding 620
- bone health 637
supplementation of mothers 640
breastmilk 19, 280, 633
- calcium 633 bronchiolitis 287, 613
BV 674
C
calcidiol - See: hydroxyvitamin D calcifediol - See: hydroxyvitamin D
calcitonin 549
calcitriol - See: dihydroxyvitamin D
calcitroic acid 450
calcium 74
absorption 17, 103, 260, 453, 567
accretion 656
balance 122
breast milk 633
cord blood 652
CVD risk of ~ supplementation 181
deposition 696
during lactation 632
epilepsy patients 590
homeostasis 102, 127, 163, 261, 354, 475, 512, 637
intestinal absorption 567
intracellular levels 511
optimal absorption 103
-rich diet 660
supplementation 109, 123, 124, 141, 245
transport 446 calculus 358 calmodulin 106
CAMP 286
cancer 183, 209, 692, 695
breast ~ 24, 184
colon ~ 161
colorectum 24, 183
esophageal ~ 464
geographical variation 209, 393
in renal TR 571
nonmelanoma skin — See: NMSC
pancreatic ~ 184, 402
prostate ~ 184, 444, 572
risk reduction 211, 571
sex specific impact 184
skin ~ 183
skin ~ prevention 399
supplementation 693
treatment 395
upper gastrointestinal ~ 467
carbamazepine 593
cardiac myocytes 548
cardiomyopathy 615
cardioprotective role 182
cardiovascular
benefits 23
disease - See: CVD
carrier in vitamin D supplementation 259
cathelicidin 247, 328, 356, 375, 572
- antimicrobial peptide - See: CAMP
CD4 count 302
cell growth
inhibition 398
prostate cells 449
central nervous system - See: CNS
cerebral palsy 597
CF 254
- European ~ bone mineralisation
guidelines 258
long term complications 254
supplementation 255
transmembrane regulator - See: CFTR
CFTR 262
chemokine 286
cholecystectomy 393
chondrocyte metabolism 379
chromosome 20 323
chronic
allograft deterioration 573
immune diseases 226
inflammation 429
kidney disease - See: CKD
circulating monocytes 489
CKD 182
clinical attachment 248 CNS
demyelination 234
tissue 476 coagulation 310
cod liver oil 14, 396, 432, 531
cognitive function 42
colon
- cancer 161
tumor 399 colorectal cancer 24, 183
compliance 156, 699
complier selection 697
congestive heart failure 615
contact hypersensitivity 233
contemporary lifestyle 634
controlled environments 59
cord blood 288, 609, 636
calcium level 652
of newborns 488 cortical bone
loss 42
mass 593
C-reactive protein - See: CRP
criteria for causality 216
Crohn's disease 213, 379, 489
supplementation 379 CRP 379, 381, 479
levels 429
crushed bones 15
cumulative intake 279
cutaneous synthesis 281
during lactation 634
cutaneous tuberculosis 422
CVD 180, 214, 528, 548, 692, 695
confirmation of ~ diagnose 698
mortality 555
risk factors 570
risk in TR 570
risk reduction 555
supplementation 693
cyclosporine A 574
CYP24A1 478
CYP27B1 449, 478, 570
cystic fibrosis - See: CF
cytochrome P450 99, 305, 445, 447, 592
- inhibitors 452
mutations in ~ enzymes 445
cytokine 42, 142, 212, 243, 261, 286, 320,328, 422, 429, 478, 479, 615, 673
cytosolic receptor 298
{SPLIT}
D
daily reference intake - See: DRI
DAS of RA 141 DBC - See: VDBC DC 262, 287, 476, 573
deficiency - See: VDD 7-dehydrocholesterol 99, 148, 227
dehydrocholesterol 322 demyelination 475
of central nervous system 234
dendritic cell - See: DC
dental caries 211, 361
- sunlight exposure 362 dental plaque 355 dentin 365
dentition 611 dermal synthesis 16
diabetes mellitus 23, 229, 232, 263, 393
- due to corticosteroid and tacrolimus
treatment 569
gestational - See: GDM
prevalence 527
risk reduction 532
type 1 213, 530, 615, 638, 678
type 1, incidence 527
type 1, latitude and risk 615
type 1, reduced risk 530
type 2 503, 531
type 2, global epidemic 528
UVB exposure 530
dialysis patients 555 dietary
guidelines esophageal cancer 469
requirements 277
supplements 362
1,25-dihydroxyvitamin D 16, 17, 98
analog 452
during pregnancy 671
functions 397
in cord blood 671
suppression 673 24,
25-dihydroxyvitamin D 320
disease
activity score - See: DAS
remission 489
DNA
- damage 228
repair 233
domestic animals 124
dose 149
daily ~ 257
during pregnancy 657, 659, 660
for breastfeeding infants 638
for fall prevention 76
-response 150
to balance efficacy and safety 695
doxercalciferol 199
draining lymph nodes 230
DRI 59
drugs
antiretroviral 299, 305
antiseizure 589
immunosuppressive 567
dual energy x-ray absorptiometry - See: DXA
DXA 86, 87, 701
EAE 380 EAR 277
ecological approach 216
ectopic calcification 365
edentulism 242
EGFR 398
elastosis 211
elderly 101
patients 105
women 74 enamel 365
hypoplasia 363 endocrine
pancreas 535
system 99 endogenous
insulin secretion 507
synthesis 526
endothelial dysfunction in renal patients - 570
enzyme-inducing medications 592
epidermal growth factor receptor - See:EGFR
epigenetic
alterations 395
control 452
fetal programming 284
mechanisms 677 epilepsy 588
BMD 591
bone turnover 592
calcium intake 590
etiology 588
fracture risk 590
obesity 591
sunlight exposure 592
supplementation 597
treatment-resistant 590
epiphyses calcification 15
epithelial
barriers 261
cells 254
erythema 227, 229 esophageal cancer 464
adenocarcinoma 466
dietary guidelines 469
incidence 465
protective factors 464
racial disparities 465
risk 464, 467
squamous cell carcinoma 466 esophageal tissue 468
esoteric tests 557
Esslinger Fitness Index 88
estimated average intake - See: EAR
estradiol 632
estrogen 671
ethnic backgrounds 57
ethnicity 119, 531
excision 418
exogenous consumption 526
experimental autoimmune encephalomyelitis - See: EAE
extra-osseous calcification 197
extra-renal tissues 502, 567
F
factorial design 694 falecalcitriol 200
falling 70, 105
definition 68
fear of ~ 69
medical costs 68
occurence 108
prevention 69, 72
reduction 108, 157
related fractures 42
risk factors 69
surrogate markers for risk 71
fast twitch muscle fibers 71
fat
accumulation of vitamin D 161
-soluble A 15
-soluble vitamin 532
stores 507 fatty fish 56
femur bone lengths 534
fetal
bone mass 118
femoral splaying 675
programming 650
skeletal development 675
Index
fetus 280 FFA 510
fibrogenesis 574 fibromyalgia 380
food
allergy 215
frequency questionnaire 700
sensitivity of infants 614
sources 90 foodstuffs 148 formula 635
fortification 620 formula-fed infants
BMD 639
fortification 60, 276
baby foods 282
dairy 507
formula 620
milk 54, 56, 124
FOXP3 expression 231
fractures 42, 68, 108, 157, 163, 255
epilepsy patients 590
renal patients 197
risk 177
risk reduction 178 frailty 45
free fatty acids - See: FFA
free radicals 333
frequency of delivery 155
G
GC protein 126
GDM 529, 533, 673
gene mutations 394
genetically modified animals 125
genomics 433
- increased risk 614
pathway 99 genotype 125, 127
gestational
- diabetes mellitus - See: GDM
supplementation 289
gingiva 355
gingival
epithelial cells 357
inflammation 244
recession in sheep 360
gingivitis 355
girls
adolescent 86, 652
premenarcheal 123
prepubertal 638 glucose
and pancreatic cancer 402
disposal 512
hepatic output 505
homeostasis 506, 512
lowering 263
supplementation 508
tolerance 505
GLUT4 504, 513
glycaemia 569
glycemic status 532
graft
- rejection 380
survival in animal models 573
group-specific component protein - See: GC
protein growth consequences 611
H
HAART 308
harmful effects 429
HbA1c 673
health assessment 701
hepatic conversion 154
high-dose therapy 75, 660
highly active antiretroviral therapy - See: HAART
hip fractures 68, 108
HIV 674
glomerular filtration rate in patients 308
mother-to-child transmission 308, 613
related factors 302
supplementation 310
transmission during gestation 656
untreated infected pregnant women 308
HLA 323
homebound pregnant women 656
homeostasis 89
calcium 102, 127, 163, 261, 354, 475, 512, 637
glucose 506, 512
immune 478
mineral 98
phosphorus 176
T cell 476
human leukocyte antigen - See: HLA
1a-hydroxylase 180, 195, 692
hydroxylation 126, 444, 447
25-hydroxyvitamin D 16, 17
- catabolism induced by
immunosuppressive drugs 567
cord blood 280, 671
deficiency 70
during pregnancy 671
half-life 149, 150
HIV infected persons 299, 309
insufficiency 70
levels and symptoms 102
recommended serum level in CF
population 258
response to vitamin D intake 25
serum concentration 54
status in neonates 638
target levels 150
toxicity 75
upper safety limit 177
usefullness of monitoring 76
hypercalcaemia 41, 103, 162, 232, 310, 381, 401, 454, 476, 558, 658, 681, 699
hypercalciuria 162, 401, 641
hyperglycaemia 511, 533
hyperinsulinemia 505, 511
hyperlipidemia 553
hyperparathyroidism 44, 105, 163, 551, 566, 568
hyperphosphatemia 195 hypertension 23, 553
hypervitaminosis D 89, 640, 658
- and teeth 363
maternal 660
hypocalcaemia 530, 609, 615
hypophosphatemia 363
hypovitaminosis D 19, 84
and CVD risk 552
clinical signs 102
myopathy 105
wintertime 24
I
IBD 373, 379
IGF-1 124, 127, 612
IgG 262
immigrants 651 immune
cells 374
dysregulation in MS 475
homeostasis 478
regulation 354
immune response 309, 356, 475, 477
tuberculosis 247 immune system 139, 612
in lungs 285 immunoglobulin G - See: IgG immunological
adaptations 672
responses to UV-induced damage 425
immunomodulation 138, 246, 373, 492, 566
after transplantation 574 immunosuppression 421, 567
by UV exposure 228, 420
therapy 226
treatments 566 immunotherapy 429
impaired mobility 591 India 61
infant
growth 121
health 632
infections 614
plasma concentration 617
prematurely born 616 infants
supplementation 61, 121, 610 infections 422
in transplantation recipients 572
infectious diseases 211
inflammation 142, 186, 310, 400, 429
chronic 429
gingival 244
markers 479
markers in neonatal immune cells 613
soluble markers 491
synovial 379
vascular 551
inflammatory
bowel disease - See: IBD
process in tuberculosis 333
skin conditions 226
influenza A 289
innate immunity 422
receptors 375
system 286, 492
system response 326, 450, 613 insufficiency
at birth 612
in CF patients 256
in HIV infected persons 299 insulin
effect of parathyroid hormone on
sensitivity 512
endogenous ~ secretion 507
insensitivity 507, 528
-like growth factor 1 - See: IGF-1
receptor 504, 505, 511
resistance 503, 508, 569
-responsive tissues 504, 510
secretion 511, 530
sensitivity 503
skeletal muscle ~ resistance 509
supplementation 508 intake
daily reference ~ - See: DRI
during pregnancy 679
frequency during lactation 633
tolerable limit 58, 640
upper level for mothers 636 intestinal
malabsorption 260
vitamin D receptor expression 423
intramuscular injection 509 intrauterine
bone growth 119
nutritional deficits 117 Islets of Langerhans 394
J
Jordan 61 K
keratinocytes 422
ketoacidosis 528
ketogenic diet 597
kidney 444, 446, 611
disease 24, 552
disease, chronic - See: CKD
killer cell 428
knee cartilage loss 142 kyphosis 255
L
lactating mothers 633
lamotrigine 596
lanolin 73
latent effects 702
latitude 139, 226, 656
and diabetes type 1 530, 615
leukocyte telomere 180
linear growth 128
lipoprotein particles 552
liver 444, 446
- meat 56
low birth weight 616
low-cost therapy 248
lower respiratory tract infection 288
low income countries 651
lungs
function in rats 285
production of vitamin D in ~ 261
lymphocytes 429, 475, 478, 489
lymphoid tissue 491 M
macrophages 329, 331, 375
mandibular bone mass 245
MART-10 452
mast cells 231 maternal
bone density loss 633
bone mineral resorption 632
fertility 672
hypervitaminosis D 660
intake 643
supplements 620
vitamin D status 128
matrix metalloproteinases - See: MMPs
maxacalcitol 199
MCTD 490 mDC 375
MDR 321, 325 melanin 20 melanocytes 420 melanoma
aetiology 425
cumulative hazard ratio 421
genetic predisposition 419
risk 424
sunburn 419 mesenchymal stem cell 127 metabolic
consumption 155
syndrome 427, 506 metalloproteinases 243
metastasis 399
microsomal enzymes 445
microvascular complications 533
milk fortification program 54
mineral
homeostasis 98
metabolism 195
mitochondrial
biogenesis 513
enzymes 445
mitogen activated protein kinase 450
MMPs 331
mobility 163 mole 418
- atypical ~ syndrome phenotype 419 monocytes 613
mood 24 mortality 41
after transplantation 575
risk for rickets 178
risk reduction 179 MS 24, 212, 232, 381, 679
primary progressive ~ 475
relapse 476, 478
risk factor 228
secondary progressive ~ 475
supplementation 476
multidrug-resistant - See: MDR multiple
primary tumours 424
sclerosis - See: MS murine
colitis model 376
models 229 muscle 504
biopsy 104
function 157
insulin-responsive tissue 510
pain 509
strength 23, 88
weakness 45, 70, 104, 108
muscle cell 98
differentiation 106
proliferation 106
striated 106 muscle fibers
composition 105
fast twitch (type II) 71
musculoskeletal
health 91
outcomes 158
pain 104
symptoms 124
mushrooms 56
mycobacteria
- immunity to ~ 330
infections 329
Mycobacterium tuberculosis 332, 572
myeloid
- cells 477
dendritic cells - See: mDC
myoblast cytoskeleton 106 myogenic differentiation 510
N
native form 201
necrotic cell populations 399
neoadjuvant therapy 468
neonatal
immune function 659
markers of inflammation 613
period 609
supplementation 620
neonate anthropometry 650, 658
nephrolithiasis 41, 47
nephroprotective role 575
neurological function 72
nitric oxide 214
NMSC 209
NNRTI 305
NOD 329
non-calcemic
- benefits 611
functions 138
non-genomic effects 107, 423
non-melanoma skin cancer - See: NMSC
non-nucleosidic reverse transcriptase inhibitor - See: NNRTI
non-skeletal benefits 22
non-specific pain 23
non-specific rheumatic diseases 105
normoglycemia 504
NRTI 307
nucleoside reverse transcriptase inhibitor – See: NRTI
nucleotide-binding oligomerization domain
- See: NOD
nulliparous women 642
O
OA 142
obese females 488
obesity 19, 243, 299, 393, 507, 514, 598, 695
in epilepsy patients 591
obstructed labor 674
omega-3 fatty acids 556
oncogene 451
optimal level 142
ossification 117
osteoarthritis - See: OA
osteoblasts 535
osteocalcin 513, 534
osteoclastic progenitors 44
osteocytes 127
osteoid seams 44
osteomalacia 14, 54, 117, 527, 652
- in successive pregnancies 652
muscle biopsy in ~ patients 104
osteopenia of prematurity 617
osteoporosis 109, 244, 534
after transplantation 568
definition of ~ 84 oxcarbazepine 595 oxidative
injuries 334
stress 334, 420
P
paediatric renal transplantation recipients 568
pale-skinned people 419
pancreas 535
pancreatic
adenocarcinoma - See: PCA
cell destruction 528
insufficiency 254
islet autoimmunity 678
pancreatic cancer 184
risk 402
sunlight 402
treatment 395
pancreatic (3-cells 504, 505, 507, 510, 528,673
dysfunction 528, 551
pancreatitis 393
parathyroid
gland 195, 201
hormone - See: PTH
levels 430
suppression 17
parental resistance to supplementation 609
parenteral cholecalciferol 660
paricalcitol 199 PBMC 488, 491
PCA 392
peak
- bone mass 84
infection rates 214
pelvic opening 208, 652
perinatal pulmonary maturation 285
periodontitis 674
aggressive 358
definition 357
during pregnancy 244
prevalence 242 periosteal apposition 117
peripheral
blood mononuclear cells - See: PBMC
tissue 200
PGs 333
phagocytes 324
phagocytosis 246, 329
pharmacological dose therapy 657
phenobarbital 593
phosphate
- binders 196
uptake 107
phosphorus homeostasis 176
photoadaption 421
photoprotective 422
phototherapy 257
physical
- activity levels 148
performance 46
pigmentary genotypes 418
pigmentation 208, 651
dark 637
pale skin 419 pigmented skin 651
PIs 305
placental
CYP24A1 gene promoter 671
infection modulation 613
transfer 680
plaque stability 552
plasma concentration 617
pleiotropic
- functions 276
steroid hormone 138
pneumonia 287, 614
polycystic ovary syndrome 509
polymorphisms 323
- in toll-like receptors 328
in VDR gene 126
polytherapy 592
post-menopausal
bone health 633
women 18, 104, 162, 421, 557
post-natal growth 658
post-transplant bone loss 566, 568
postural instability 71
precursor lesions 418
preeclampsia 25, 120, 533, 672
supplementation 673
pregnancy 120, 609
adolescent 652
adverse 533
hormones 529
periodontitis 244
supplementation 609, 658, 680
untreated HIV-infected women 308
pregnant women 278, 529, 534, 650
- oral health 245
premalignant lesions 394
premenarcheal girls 123
prepubertal girls 638
preterm infants 616
rachitic respiratory distress 617
primary prevention trial 697
primidone 593
proliferation 445, 476
- of T cells 324
prostaglandins - See: Pgs
prostate
cancer 184, 444, 572
cell growth 449
cells 447, 450, 451
tissue 448
prostatic hypertrophy 449
protease inhibitors - See: Pis
proteinuria 194, 574
psoriasis 25, 453
psoriatric arthritis patients 490
psychomotor function 108
PTH 87, 102, 119, 196, 259, 372, 451, 511, 512, 549, 568, 574, 609, 617
insulin sensitivity 512
levels 260
secretion 453
suppression 198 public health programs 63
pulmonary
- disease 254
infections 284
purdah (use of veils) 651
putative risk factor 476
pyrazinamide 334
R
RA 138, 214, 378, 490
- patients 140
rachitic respiratory distress 617
racial backgrounds 57
esophageal cancer 465
RANKL 230
RAS 202, 551, 574
RDA 89, 696
reactive
nitrogen intermediates - See: RNI
oxygen species - See: ROS receptor
activator of NFkB ligand - See: RANKL
agonists 430
recommended dietary allowance - See: RDA
recruitment strategy 697
reflux esophagitis 466
relapsing remitting multiple sclerosis - See:RRMS
remineralization 363
renal
cells 450
failure 330
osteodystrophy 197
reabsorption of calcium 632
stones 161, 162, 179, 430 renal patients
arteriosclerosis 570
bone fracture 197
endothelial dysfunction 570
supplementation 575
renal transplantation recipients 567
cancer 571
paediatric 568
skin cancer 571
supplementation 575 renin-angiotensin system - See: RAS respiratory
epithelial cells 286
muscle weakness 288
tract infections 284
viral infections 213 rheumatoid arthritis - See: RA
rickets 14, 117, 527
and antiseizure drugs 589
resurgence 18, 610, 618, 634
risk factors 635 risk factors 279
during fetal period and lactation 636
RNI 334 ROS 333
RRMS 475
S
safety limit 696
sarcopenia 42, 45, 71
schizophrenia 678
screening 619
secosteroid hormone 276
seizures 588
selective receptor modulator concept 101
serum
biomarkers 21
hydroxyvitamin D 40, 101, 506, 526
insulin 507
levels 40, 432
minimal level 430
parathyroid hormone 502
triglycerides 508
sex specific impact of cancer 184
SGA 120, 676
side effects 696
signaling pathways 505
Simplified Acute Physiology Score II 179
single-nucleotide polymorphism - See: SNP
skeletal
bone resorption 163
craniotabes in newborns 680
mineralization 45
muscle insulin resistance 509
pain 104 skin 40
aging 148
cancer 183
cancer in renal transplantation recipients
cancer, nonmelanoma - See: NMSC
cancer prevention 399
cancer risk 418
colour 426, 431
pale 419
pigmentation 208, 651
type 281
UVB irradiation 227
SLE 378, 379, 490, 492
small for gestational age - See: SGA smoking 321
SNP 326, 423, 427, 614
solar elastosis 426 spaying index 118
SPB 674
spontaneous preterm birth - See: SPB
squamous
- cell carcinomas 464
dysplasia 467
standardized measuring method 60
statistical power 700
striated muscle cells 106 stunted growth 116, 612
sufficiency
definition 656 sunburn
melanoma risk 419
sun exposure 14, 226, 256, 656
children 280
decreased cutaneous penetration 380
dental caries 362
epilepsy patients 592
pancreatic cancer 402
regular 422
seasonal variety 701
tuberculosis treatment 331 sunscreen 20, 634
supplementation 57, 75, 109, 123, 141, 151,245, 429, 432
adverse effects 122
and cardiovascular health 570
birth weight/length 676
developing countries 657
during lactation 633
efficacy 156
form 155
individualisation 257
nursing homes 59
responsiveness 123
seasonal effects 154
teeth defects 362
to both mother and infant 642
viral response 572
supra-physiologic dosages 570
supravalvular aortic stenosis 634
surfactants 286
surrogate marker of health 143
survival of CKD patients 201
synovial inflammation 379
systemic lupus erythematosus - See: SLE
T
T cell 376, 573
homeostasis 476
response 478
teeth 15
- attachment apparatus 355
composition 354
telomerase activity 180, 399
telomeric aging 180
temperate climates 322
tender joint count 141
tenofovir 307
teriparatide 360
testosterone 72
tetanus toxoid vaccination 490
thymus receptor binding assay 448
thyroid disease patients 490
tibian length 123
tilt of the earth 20
tissue
diseases 373
epidermal 376
inhibitor 488
mixed connective disease 488
non-traditional target 98
vitamin D receptor expression 101
TLRs 326
tobacco smoke 392 toddlers
- outdoor exposure 281 tolerable upper intake level - See: UL
toll-like receptors - See: TLRs
tomography 86, 118
tooth
development 362
loss 243, 360, 363
topiramate 596 toxicity 21, 103, 381
concerns 640
symptoms 59
TR 566
cancer 571
CVD 570
infections 572
transcription-independent effects 423
transplantation 263
recipients - See: TR
supplementation 567 Treg cells 380 tuberculosis 331
cutaneous 422
immune response 247
inflammatory process 333
seasonal variations 322
sunlight 331 tuberculous meningitis 332 tumor 426
colon 399
multiple primary ~s 424
suppressor 450
U
UC 213 UL 162
ulcerative colitis - See: UC
unhealthy children 89
unwanted systemic effects 373
upper gastrointestinal cancers 467
up-regulation
of genes 448
of p27 proteins 398 uremic patients 508
UVB
exposure 15, 120
exposure of face only 639
index for men 210
radiation 183, 322
risk of diabetes type 1 530
treatment 260
UV light 16
- wavelength 227, 233
V
vaccination
BCG 330
reduced efficacy 231
tetanus toxoid 490 valproate 594
vascular
calcification 182, 197, 202
endothelial growth factor - See: VEGF
function 552
inflammation 551
tissue 548
vBMD 44
VDBP 194, 200, 396, 670
- during pregnancy 671
VDD 650
definition 549
predisposition 557
prevalence 40, 550
risk groups 40
secondary 652
vulnerable subgroups 54
VDR 71, 99, 100, 139, 180, 200, 261, 298, 356, 372, 374, 397, 423, 444, 454, 468, 477, 503, 510, 570, 611, 672, 692
agonists 573
alkylating derivative 401
deficient mice 125, 139
immuno-staining 286
muscle cells 106
phenotype 123
polymorphism 247, 324, 332, 361, 468, 531, 534, 676
polymorphism and muscle function 105
skin cancer 424
tuberculosis patients 324
vegetarian diet 330
VEGF 332
veils 651
Viosterol 16
viral infections 287, 422
vitamin D binding protein - See: VDBP
vitamin D receptor - See: VDR
vitiligo 429
volumetric bone mineral density - See: vBMD
W
wheezing 288 window-glass 20
winter 656
wintertime hypovitaminosis D 24
women of child-bearing age 608